Compare SCZM & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCZM | SLN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Canada | United Kingdom |
| Employees | 455 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 585.2M | 678.0M |
| IPO Year | N/A | 2010 |
| Metric | SCZM | SLN |
|---|---|---|
| Price | $8.88 | $11.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $42.60 |
| AVG Volume (30 Days) | 400.4K | ★ 647.9K |
| Earning Date | 05-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | $79.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.61 | $4.19 |
| 52 Week High | $17.65 | $17.58 |
| Indicator | SCZM | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.32 | 42.56 |
| Support Level | $8.55 | $4.70 |
| Resistance Level | $10.33 | $15.28 |
| Average True Range (ATR) | 0.50 | 0.58 |
| MACD | -0.12 | -0.23 |
| Stochastic Oscillator | 39.79 | 10.46 |
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.